Tag Archives: PATIENTS

Patients who had more severe COVID-19 may be the best donors for convalescent plasma therapy

Sex, age, and severity of disease may be useful in identifying COVID-19 survivors who are likely to have high levels of antibodies that can protect against the disease, according to a new study co-led by researchers at Johns Hopkins Bloomberg School of Public Health. The findings suggest that older males who have recovered from COVID-19… Read More: Patients who had more severe COVID-19 may be the best… »

As a medical student, you find potential patients everywhere

An excerpt from Diary of a Medical Student. As a medical student, you find potential patients everywhere. Whether you’re on an airplane or on a romantic dinner date, we’ve all heard those famous words, “Is there a doctor in the house?!” Here are some of my favorite “patient” encounters. The best friend curbside. I was… Read More: As a medical student, you find potential patients everywhere »

Gilead’s Veklury wins expanded FDA nod for moderate COVID-19 patients despite mixed data

Amid daily headlines about COVID-19 vaccines and trends, Gilead’s Veklury, also known as remdesivir, remains the only antiviral drug authorized to treat the illness. With a new move from the FDA, the medicine’s emergency green light is a little broader—despite some lingering questions about its efficacy. Under the expanded emergency use authorization (EUA), all hospitalized… Read More: Gilead’s Veklury wins expanded FDA nod for moderate COVID-19 patients… »

FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis

FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis Print this page Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically… Read More: FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with… »